Organogenesis Holdings Inc. May 2, 2024 at 4:00 AM UTC OriginalELI5 Organogenesis Achieves Primary Endpoint in Phase 3 Clinical Trial of ReNu® for Knee Osteoarthritis Statistically significant (p=0.0177) reduction in knee pain at six monthsStatistically significant (p
